Identification of Dysregulated microRNAs in Glioblastoma Stem-like Cells

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults. Despite multimodal therapy, median survival is poor at 12-15 months. At the molecular level, radio-/chemoresistance and resulting tumor progression are attributed to a small fraction of tumor cells, termed glioblastoma stem-like cells (GSCs). These CD133-expressing, self-renewing cells display the properties of multi-lineage differentiation, resulting in the heterogenous composition of GBM. MicroRNAs (miRNAs) as regulators of gene expression at the post-transcriptional level can alter many pathways pivotal to cancer stem cell fate. This study explored changes in the miRNA expression profiles in patient-derived GSCs altered on differentiation into glial fiber acid protein (GFAP)-expressing, astrocytic tumor cells using a polymerase chain reaction (PCR) array. Initially, 22 miRNAs showed higher expression in GSCs and 9 miRNAs in differentiated cells. The two most downregulated miRNAs in differentiated GSCs were miR-17-5p and miR-425-5p, whilst the most upregulated miRNAs were miR-223-3p and let-7-5p. Among those, miR-425-5p showed the highest consistency in an upregulation in all three GSCs. By transfection of a 425-5p miRNA mimic, we demonstrated downregulation of the GFAP protein in differentiated patient-derived GBM cells, providing potential evidence for direct regulation of miRNAs in the GSC/GBM cell transition.

Automated summary

This study explored changes in miRNA expression profiles in patient-derived glioblastoma stem-like cells (GSCs) upon differentiation into glial fiber acid protein (GFAP)-expressing astrocytic tumor cells. The results showed that miR-17-5p and miR-425-5p were downregulated, while miR-223-3p and let-7-5p were upregulated in differentiated cells. Among them, miR-425-5p consistently showed the highest downregulation in all GSCs. Transfection of a 425-5p miRNA mimic demonstrated downregulation of GFAP protein in differentiated patient-derived GBM cells, suggesting direct regulation of miRNAs in the GSC/GBM cell transition.